This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Becton, Dickinson and Company (BDX) Ahead of Earnings?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If You Invested $1000 in Becton Dickinson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
BD (BDX) Hits a New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
A slew of strategic acquisitions are driving the top line for BD (BDX).
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost
by Zacks Equity Research
Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
by Debanjana Dey
Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
by Zacks Equity Research
BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
BD's (BDX) Latest Buyout to Enhance its Digital Capabilities
by Zacks Equity Research
BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.
BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm
by Zacks Equity Research
BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
BD's (BDX) Buyout of Venclose to Improve Patient Outcome
by Zacks Equity Research
BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
Top Analyst Reports for Accenture, Raytheon & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corporation (RTX), and Becton, Dickinson, and Company (BDX).
BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.
Becton Dickinson (BDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 4 Earnings Roster: BDX, ZBH & More
by Trina Mukherjee
The Medical Product companies' Q3 results are likely to reflect huge adoption of their COVID-related support products. Let's see how BDX, ZBH, ABC and XRAY are poised ahead of their earnings releases.